First Horizon Advisors Inc. Buys Shares of 356 BioNTech SE (NASDAQ:BNTX)

First Horizon Advisors Inc. purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 356 shares of the company’s stock, valued at approximately $38,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Baillie Gifford & Co. increased its holdings in shares of BioNTech by 15.5% in the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock valued at $934,612,000 after purchasing an additional 1,152,541 shares during the period. Clearbridge Investments LLC increased its stake in BioNTech by 41.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock valued at $52,595,000 after buying an additional 142,344 shares during the period. DekaBank Deutsche Girozentrale lifted its position in BioNTech by 43.1% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock worth $44,610,000 after buying an additional 127,951 shares in the last quarter. abrdn plc acquired a new stake in shares of BioNTech during the 4th quarter valued at $10,961,000. Finally, Bamco Inc. NY grew its holdings in shares of BioNTech by 123.1% during the 3rd quarter. Bamco Inc. NY now owns 158,911 shares of the company’s stock valued at $17,264,000 after acquiring an additional 87,686 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 0.8 %

Shares of BioNTech stock opened at $90.13 on Thursday. BioNTech SE has a 12-month low of $85.21 and a 12-month high of $125.83. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $90.47 and a two-hundred day moving average price of $95.95. The stock has a market capitalization of $21.43 billion, a P/E ratio of 21.88 and a beta of 0.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. Equities analysts expect that BioNTech SE will post -1.74 earnings per share for the current year.

Analysts Set New Price Targets

BNTX has been the subject of several recent research reports. TD Cowen increased their price objective on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a report on Tuesday. UBS Group dropped their target price on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. HC Wainwright lifted their price target on BioNTech from $107.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. dropped their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. Finally, BMO Capital Markets cut their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $118.82.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.